Market Summary
USD13.36+0.09
Delayed0.68%
MD Stock Price
MD RSI Chart
MD Valuation
MD Price/Sales (Trailing)
MD Profitability
MD Fundamentals
MD Revenue
MD Earnings
Price Action
52 Week Range
12.8423.95
(Low)(High)
Last 7 days
-2.1%
Last 30 days
-4.9%
Last 90 days
-14.6%
Trailing 12 Months
-30.7%
MD Financial Health
MD Investor Care
Peers (Alternatives to MEDNAX)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HCA | 73.0B | 60.9B | -4.91% | 25.24% | 12.73 | 1.2 | 1.94% | -15.77% |
LH | 20.7B | 14.8B | -2.77% | -13.32% | 16.22 | 1.39 | -6.96% | -52.35% |
DGX | 15.0B | 9.6B | -8.90% | -4.59% | 18.89 | 1.56 | -10.08% | -57.84% |
| MID-CAP | ||||||||
UHS | 9.9B | 13.6B | -10.37% | 3.84% | 14.64 | 0.74 | 5.04% | -26.87% |
DVA | 8.5B | 11.7B | 9.28% | -3.24% | 16.63 | 0.73 | 0.42% | -43.11% |
THC | 7.2B | 19.4B | -1.91% | 7.28% | 7.07 | 0.37 | 0.01% | -33.70% |
EHC | 6.1B | 4.4B | -5.92% | 18.26% | 22.47 | 1.4 | 8.15% | -30.89% |
SGRY | 4.5B | 2.6B | -10.50% | -11.04% | -48.8 | 1.71 | 13.01% | -143.24% |
SEM | 3.4B | 6.4B | -7.51% | 11.50% | 19.08 | 0.54 | 2.26% | -46.98% |
| SMALL-CAP | ||||||||
RDNT | 1.7B | 1.5B | 6.01% | 44.82% | -126.07 | 1.14 | 10.24% | -173.11% |
ADUS | 1.4B | 976.1M | -21.09% | 3.91% | 28.65 | 1.47 | 10.19% | 12.37% |
BKD | 645.6M | 2.9B | -18.53% | -39.08% | -3.53 | 0.22 | 7.97% | -101.02% |
CYH | 419.8M | 12.2B | -47.61% | -42.62% | -104.96 | 0.03 | -2.06% | -101.36% |
SSY | 6.7M | 46.8M | -7.74% | -13.61% | -2.44 | 0.14 | 12.07% | -154.21% |
Financials for MEDNAX
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 0.4% | 1,981 | 1,972 | 1,957 | 1,960 | 1,947 |
| Operating Expenses | 1.0% | 1,817 | 1,799 | 1,752 | 1,744 | 1,731 |
| S&GA Expenses | -1.0% | 229 | 231 | 239 | 248 | 258 |
| EBITDA | -16.5% | 157 | 188 | 200 | 202 | - |
| EBITDA Margin | -17.2% | 0.08* | 0.10* | 0.10* | 0.10* | - |
| Earnings Before Taxes | 60.3% | 130 | 81.00 | 107 | 112 | 106 |
| EBT Margin | -24.6% | 0.04* | 0.05* | 0.06* | 0.05* | - |
| Interest Expenses | -3.6% | 38.00 | 40.00 | 46.00 | 54.00 | 63.00 |
| Net Income | 53.4% | 102 | 66.00 | 84.00 | 84.00 | 92.00 |
| Net Income Margin | -21.8% | 0.03* | 0.04* | 0.04* | 0.05* | - |
| Free Cahsflow | 48.4% | 167 | 112 | 90.00 | 61.00 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | -1.2% | 2,320 | 2,348 | 2,332 | 2,370 | 2,341 |
| Current Assets | -4.5% | 409 | 428 | 424 | 459 | 440 |
| Cash Equivalents | -37.7% | 6.00 | 10.00 | 9.00 | 14.00 | 7.00 |
| Net PPE | -0.5% | 73.00 | 73.00 | 72.00 | 72.00 | 72.00 |
| Goodwill | 0% | 1,532 | 1,532 | 1,532 | 1,532 | 1,529 |
| Liabilities | -3.2% | 1,410 | 1,456 | 1,473 | 1,524 | 1,464 |
| Current Liabilities | -33.4% | 284 | 427 | 352 | 329 | 270 |
| Shareholder's Equity | 2.0% | 910 | 892 | 859 | 845 | 877 |
| Retained Earnings | 16.0% | -74.86 | -89.06 | -118 | -149 | -176 |
| Additional Paid-In Capital | 0.3% | 987 | 984 | 981 | 997 | 1,054 |
| Shares Outstanding | 0.8% | 84.00 | 83.00 | 83.00 | 84.00 | 87.00 |
| Minority Interest | NaN% | - | - | - | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | -2.1% | 164 | 167 | 112 | 90.00 | 61.00 |
| Share Based Compensation | -8.8% | 15.00 | 16.00 | 17.00 | 18.00 | 20.00 |
| Cashflow From Investing | 26.2% | -42.03 | -56.95 | -61.30 | -96.42 | -68.98 |
| Cashflow From Financing | 74.9% | -122 | -487 | -400 | -317 | -254 |
| Buy Backs | -0.4% | 88.00 | 89.00 | 87.00 | 68.00 | 4.00 |
Risks for MD
What is the probability of a big loss on MD?
100%
Probability that MEDNAX stock will be more than 20% underwater in next one year
84.2%
Probability that MEDNAX stock will be more than 30% underwater in next one year.
63.9%
Probability that MEDNAX stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does MD drawdown profile look like?
Y-axis is the maximum loss one would have experienced if MEDNAX was unfortunately bought at previous high price.
Drawdowns
Returns for MD
Cumulative Returns on MD
-11.7%
10-Year Cumulative Returns
-20.8%
7-Year Cumulative Returns
-22.2%
5-Year Cumulative Returns
-5.6%
3-Year Cumulative Returns
What are the long-term rolling returns for MD?
FIve years rolling returns for MEDNAX.
Annualized Returns
Which funds bought or sold MD recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -8.15 | -15,040 | 176,862 | -% |
2023-05-25 | Legato Capital Management LLC | unchanged | - | 1,426 | 425,382 | 0.08% |
2023-05-23 | Capital Impact Advisors, LLC | added | 6.26 | 37,591 | 605,763 | 0.74% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -1.54 | -79,701 | 6,614,300 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 19.32 | 306,000 | 1,857,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -3.22 | -668,000 | 22,438,000 | 0.03% |
2023-05-17 | Advisory Services Network, LLC | sold off | - | - | - | -% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -3.38 | -38,000 | 1,213,000 | -% |
2023-05-16 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | sold off | -100 | -805,100 | - | -% |
2023-05-16 | CAROLINAS WEALTH CONSULTING LLC | unchanged | - | 11.00 | 3,221 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
MEDNAX News
Schedule 13G FIlings of MEDNAX
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 10, 2023 | alliancebernstein l.p. | 10.0% | 8,392,304 | SC 13G/A | |
| Feb 14, 2023 | alliancebernstein l.p. | 7.8% | 6,468,122 | SC 13G/A | |
| Feb 14, 2023 | earnest partners llc | 7.9% | 6,546,580 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 11.72% | 9,738,017 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 16.5% | 13,672,143 | SC 13G/A | |
| Jan 20, 2023 | starboard value lp | 4.0% | 3,348,578 | SC 13D/A | |
| Dec 02, 2022 | starboard value lp | 7.1% | 5,915,000 | SC 13D/A | |
| Feb 14, 2022 | arrowmark colorado holdings llc | 3.10% | 2,683,879 | SC 13G/A | |
| Feb 14, 2022 | alliancebernstein l.p. | 8.5% | 7,359,083 | SC 13G/A |
MD Fair Value
MEDNAX fair value in different scenarios
The table shows the Fair Value estimates for MEDNAX for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 11.32 -15.27% | 14.02 4.94% | 20.33 52.17% | 26.00 94.61% | 30.28 126.65% |
| Current Inflation | 10.98 -17.81% | 13.52 1.20% | 19.29 44.39% | 24.45 83.01% | 27.50 105.84% |
| Very High Inflation | 10.53 -21.18% | 12.86 -3.74% | 17.95 34.36% | 22.49 68.34% | 24.17 80.91% |
Historical MEDNAX Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of MEDNAX
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 26, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 144 | Notice of Insider Sale Intent | |
| May 22, 2023 | 4 | Insider Trading | |
| May 19, 2023 | 144 | Notice of Insider Sale Intent | |
| May 18, 2023 | 144 | Notice of Insider Sale Intent | |
| May 15, 2023 | 4 | Insider Trading | |
| May 15, 2023 | 4 | Insider Trading | |
| May 15, 2023 | 4 | Insider Trading | |
| May 15, 2023 | 4 | Insider Trading | |
| May 15, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for MD
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-25 | ORDAN MARK S | sold | -437,580 | 13.26 | -33,000 | - |
2023-05-19 | Weis Shirley A | sold | -13,725 | 13.63 | -1,007 | - |
2023-05-18 | Weis Shirley A | sold | -243,805 | 13.55 | -17,993 | - |
2023-05-15 | Pickert Curtis | gifted | - | - | -5,984 | evp, chief operating officer |
2023-05-12 | Young Sylvia Jean | acquired | - | - | 10,831 | - |
2023-05-11 | Starcher John M. Jr. | acquired | - | - | 10,965 | - |
2023-05-11 | Linynsky Laura A | acquired | - | - | 10,965 | - |
2023-05-11 | SANSONE GUY P | acquired | - | - | 10,965 | - |
2023-05-11 | Weis Shirley A | acquired | - | - | 10,965 | - |
2023-05-11 | Rucker Michael A. | acquired | - | - | 10,965 | - |
MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was founded in 1979 and is based in Sunrise, Florida.
MD Income Statement
2023-03-31Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |||
| Income Statement [Abstract] | ||||
| Net revenue | $ 491,008 | $ 482,229 | ||
| Operating expenses: | ||||
| Practice salaries and benefits | 362,235 | 343,155 | ||
| Practice supplies and other operating expenses | 30,720 | 28,489 | ||
| General and administrative expenses | 59,059 | 61,287 | ||
| Depreciation and amortization | 8,953 | 8,769 | ||
| Transformational and restructuring related expenses | 0 | 1,421 | ||
| Total operating expenses | 460,967 | 443,121 | ||
| Income from operations | 30,041 | 39,108 | ||
| Investment and other income | 634 | 875 | ||
| Interest expense | (10,390) | (11,818) | ||
| Loss on early extinguishment of debt | 0 | (57,016) | ||
| Equity in earnings of unconsolidated affiliate | 427 | 505 | ||
| Total non-operating expenses | (9,329) | (67,454) | ||
| Income (loss) from continuing operations before income taxes | 20,712 | (28,346) | ||
| Income tax benefit | (6,506) | 7,401 | ||
| Income (loss)from continuing operations | 14,206 | (20,945) | ||
| Loss from discontinued operations, net of tax | 0 | (247) | ||
| Net Income (loss) | 14,206 | (21,192) | ||
| Net loss attributable to noncontrolling interest | 0 | 4 | ||
| Net Income (loss) attributable to Pediatrix Medical Group, Inc. | 14,206 | (21,188) | ||
| Unrealized holding gain (loss) on investments, net of tax of $227 and $894 | 604 | (2,668) | ||
| Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc. | $ 14,810 | $ (23,856) | ||
| Net (loss) income attributable to Pediatrix Medical Group, Inc.: | ||||
| Basic | $ 0.17 | $ (0.25) | ||
| Diluted | $ 0.17 | $ (0.25) | ||
| Weighted average common shares: | ||||
| Basic | 81,894 | 85,405 | ||
| Diluted | [1] | 82,318 | 85,405 | |
| ||||
MD Balance Sheet
2023-03-31Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 6,124 | $ 9,824 |
| Short-term investments | 96,709 | 93,239 |
| Accounts receivable, net | 278,739 | 296,787 |
| Prepaid expenses | 14,951 | 14,878 |
| Other current assets | 12,069 | 13,261 |
| Total current assets | 408,592 | 427,989 |
| Property and equipment, net | 72,928 | 73,290 |
| Goodwill | 1,532,092 | 1,532,092 |
| Intangible assets, net | 17,487 | 18,491 |
| Operating and finance lease right-of-use assets | 66,793 | 66,924 |
| Deferred income tax assets | 102,778 | 105,925 |
| Other assets | 119,381 | 123,176 |
| Total assets | 2,320,051 | 2,347,887 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 226,675 | 374,225 |
| Current portion of debt and finance lease liabilities, net | 14,914 | 14,898 |
| Current portion of operating lease liabilities | 21,058 | 21,589 |
| Income taxes payable | 21,571 | 16,271 |
| Total current liabilities | 284,218 | 426,983 |
| Line of credit | 114,000 | 4,000 |
| Long-term debt and finance lease liabilities, net | 628,814 | 632,381 |
| Long-term operating lease liabilities | 43,977 | 44,213 |
| Long-term professional liabilities | 268,922 | 275,629 |
| Deferred income tax liabilities | 32,703 | 33,638 |
| Other liabilities | 37,646 | 39,411 |
| Total liabilities | 1,410,280 | 1,456,255 |
| Commitments and contingencies | ||
| Shareholders' equity: | ||
| Preferred stock; $.01 par value; 1,000 shares authorized; none issued | 0 | 0 |
| Common stock; $.01 par value; 200,000 shares authorized; 83,634 and 82,947 sharesissued and outstanding, respectively | 836 | 829 |
| Additional paid-in capital | 986,923 | 983,601 |
| Accumulated other comprehensive loss | (3,131) | (3,735) |
| Retained deficit | (74,857) | (89,063) |
| Total shareholders' equity | 909,771 | 891,632 |
| Total liabilities and shareholders' equity | $ 2,320,051 | $ 2,347,887 |